( CHICAGO--(BUSINESS WIRE)--Jun 25 2007 ...)Lipitor Reduced the Risk of Coronary Events by Half and Stroke by,Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who,Experienced a Recent Stroke,Health

CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - Pfizer announced today that Lipitor (atorvastatin calcium) Tablets 80 mg reduced the risk of stroke, coronary heart disease events and major coronary events in type 2 diabetes patients who had no known coronary heart disease but who had experienced a recent stroke or mini-stroke, compared with placebo. The results are from a new analysis of the landmark Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, and were presented at the 67th Annual Scientific Sessions of the American Diabetes Association.

According to the National Institute of Diabetes and Digestive and Kidney Diseases, the risk for stroke is two to four times higher among people with diabetes, and heart disease and stroke account for nearly two-thirds of deaths in people with diabetes.

"People with type 2 diabetes who have had a stroke are at a much higher risk of having a second stroke, a coronary heart disease event or revascularization procedure than people without type 2 diabetes," said Dr. Michael Welch, lead SPARCL investigator, neurologist and president of Rosalind Franklin University of Medicine & Science. "In this analysis of patients with type 2 diabetes with no known coronary heart disease, we found Lipitor to be effective in reducing these risks."

In this pre-specified analysis (n=794), Lipitor reduced the risk of stroke by 30 percent, and coronary heart disease events and major coronary events by 51 percent, compared with placebo. Coronary heart disease events include cardiac death, heart attack, resuscitated cardiac arrest, unstable chest pain, revascularization, or chest pain requiring emergency hospitalization. Major coronary events include cardiac death, heart attack, or resuscitated cardiac arrest.

An additional analysis evaluated 781 patients in the SPARCL trial who were classified as having metabolic syndrome and who had a recent stroke o
'"/>

Page: 1 2 3
Related medicine technology :

1. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
2. Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients
3. Two New Imaging Studies Show Higher Dose Lipitor Stopped the Progression of Atherosclerosis
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
6. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
9. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
10. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
11. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat